Fibryga Powder, For Solution
Product Images NDC 68982-349

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Fibryga (NDC 68982-349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Octapharma Usa Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image File (Img0001)

This image shows a formula for calculating the dose of Fibryga (Fibrinogen (Human)) powder for solution for intravenous use. The formula uses target and measured fibrinogen levels to determine the dose in mg/kg body weight.*

FDA Label Image

Image File (Img0002)

A formula describing the calculation of dose based on target fibrinogen level and measured fibrinogen level, expressed as dose in mg/kg body weight for Fibryga (Fibrinogen Human) powder for solution intravenous.*

FDA Label Image

Image File (Img0003)

An instructional illustration showing the use of the Nextaro transfer device. It depicts how to peel back the protective cover from the top of the device, with a hand lifting the cover upwards. The device is held by another hand, highlighting proper handling before use.*

FDA Label Image

Image File (Img0004)

An instructional illustration showing a vial labeled as a diluent and a cap, indicating the step of adding or connecting the cap to the diluent vial, likely as part of the preparation process for reconstituting Fibryga (Fibrinogen Human) powder for solution.*

FDA Label Image

Image File (Img0005)

An instructional illustration showing the removal of a cap from a vial and the vial labeled as a diluent vial, used for preparing a solution. The diagram is labeled as Fig. 3.*

FDA Label Image

Image File (Img0006)

An instructional illustration showing the process of attaching a diluent vial upside down onto a Fibryga bottle for preparation. The Fibryga bottle is labeled with the product name, and the diluent vial is positioned above it with an arrow indicating downward placement.*

FDA Label Image

Image File (Img0007)

An instructional diagram shows the process of connecting an empty diluent vial to a reconstituted Fibryga bottle, illustrating the preparation step for intravenous administration of Fibryga (Fibrinogen Human) powder for solution.*

FDA Label Image

Image File (Img0008)

An instructional illustration showing the process of using a syringe to withdraw or inject liquid from a vial labeled 'Reconstituted FIBRYGA bottle.' The image depicts the syringe pressing down and twisting as part of the procedure.*

FDA Label Image

Image File (Img0009)

An instructional illustration showing a reconstituted Fibryga (Fibrinogen Human) bottle attached to a syringe. The diagram indicates the process of drawing the solution from the bottle into the syringe for intravenous use.*

FDA Label Image

Image File (Img0010)

An instructional diagram illustrating the process of attaching an empty Fibryga bottle to a syringe for preparation. The illustration indicates the bottle being inverted and connected to the syringe before mixing or drawing liquid.*

FDA Label Image

Image File (Img0011)

A data table showing virus reduction factors in log10 for various production steps of Fibryga, a fibrinogen (human) powder for solution intravenously. The table lists virus reduction at S/D treatment and nanofiltration steps against enveloped viruses (HIV-1, PRV, BVDV) and non-enveloped viruses (HAV, PPV), with cumulative virus reduction factors also presented.*

FDA Label Image

Image File (Img0012)

This table presents pharmacokinetic parameters including half-life, Cmax, AUC, incremental IVR, clearance, mean residence time, and volume of distribution for Fibryga (Fibrinogen Human) powder for solution 20 mg/mL. Data are shown as mean ± SD and range for adult and adolescent patients, pediatric patients aged 6 to under 12 years, and pediatric patients under 6 years.*

FDA Label Image

Image File (Img0013)

An instructional illustration showing the use of the Nextaro transfer device. It depicts a hand lifting the cap of the device, highlighting the initial step in the transfer process.*

FDA Label Image

Image File (Img0014)

An instructional diagram showing a step involving a vial cap with an arrow pointing downward towards a diluent vial below. The image likely illustrates part of the reconstitution or preparation process for Fibryga 20 mg/mL powder for solution, indicating the interaction with the diluent vial.*

FDA Label Image

Image File (Img0015)

An instructional illustration showing the process of removing a cap or stopper from a diluent vial, labeled "Diluents vial." This figure is part of preparation instructions for a powder for solution product administered intravenously.*

FDA Label Image

Image File (Img0016)

An instructional illustration showing a diluent vial with a blue cap being inserted into a Fibryga bottle. The Fibryga bottle is labeled and contains powder for solution, indicating preparation steps for the intravenous plasma derivative product Fibryga by Octapharma USA Inc.*

FDA Label Image

Image File (Img0017)

An instructional illustration showing the process of adding an empty diluent vial to a reconstituted Fibryga (Fibrinogen (Human)) bottle, a powder for solution intravenous product by Octapharma USA Inc. The image depicts attaching the diluent vial to the Fibryga bottle, indicating preparation steps for intravenous administration.*

FDA Label Image

Image File (Img0018)

An instructional diagram showing reconstitution of Fibryga (Fibrinogen Human) powder for solution. The image illustrates a syringe being inserted and twisted into a Fibryga bottle for intravenous use.*

FDA Label Image

Image File (Img0019)

Illustration showing a reconstituted Fibryga bottle being used with a syringe. The image depicts the connection of the syringe to the bottle for drawing the intravenous fibrinogen solution, highlighting the preparation step for administration.*

FDA Label Image

Image File (Img0020)

An instructional diagram showing how to assemble the Fibryga intravenous solution system. It depicts an empty Fibryga bottle being attached upside down onto a device, with an arrow indicating insertion, and a syringe connected to the assembly with a twisting motion indicated for securing.*

FDA Label Image

Image File (Img0021)

Fibryga 20 mg/mL lyophilized powder for solution containing human fibrinogen, for intravenous administration. The label indicates it is manufactured by Octapharma and distributed by Octapharma USA Inc. It includes storage instructions and a 1g range dosage reference.*

FDA Label Image

Image File (Img0022)

The image shows the unfolded carton packaging for Fibryga 1g, a lyophilized powder for reconstitution containing Fibrinogen (Human). The label indicates the product is for intravenous use only and is manufactured by Octapharma USA Inc. The packaging details storage instructions, contents including one bottle with lyophilized powder and one vial of diluent, and lists inactive ingredients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.